Trial Profile

A Phase 1 Study of LY2606368 in Patients With Advanced Cancer.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Prexasertib (Primary)
Indications Anal cancer; Cancer; Carcinoma; Head and neck cancer; Non-small cell lung cancer; Skin cancer; Solid tumours; Squamous cell cancer; Vulvovaginal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

11 Apr 2018 Results (n=101) of dose expansion phase published in the Clinical cancer research: an official journal of the American Association for Cancer Research
05 Apr 2017 Results (n=71) of a clinical biomarker analysis of prexasertib in patients with advanced head and neck squamous cancer and squamous cell carcinoma of the anus, presented at the 108th Annual Meeting of the American Association for Cancer Research.
19 Apr 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com